Eurobio-Scientific SA ALERS
EURONEXT · France · Health Technology
€25.100.00 (0.00%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026 Revenue up 4.5% to 84.5 M€ Proprietary products account for 37% of revenue46% of revenue generated outside France Free cash flow of €4 million after investmentsNet debt of €147.4 million, including the EB Development shareholder loanAcquisition of CareDx’s Lab Solutions business finalized on June 30, 2026 Paris, September 24, 2026 – 17h40 - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life
FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 millionContinuation of the Group’s strategy: Proprietary products: 37% of revenueInternational expansion: 47% of revenue generated outside France Paris, July 28, 2026 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today reports its half-year revenue as of June 30, 2026. 5% revenue growthAs of June 30, 2026, Eurobio Scien
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leaderCreation of a global leading provider of kits for genomic typing and transplantation diagnosticsAcquisition of a 100% proprietary products portfolioDeeper capabilities and larger scale with technological and commercial complementarities Paris, July 1st, 2026 ,8 AM CET Eurobio Scientific (FR0013240934, ALERS, PE
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.